Theratechnologies Inc Stock Price, News & Analysis

MONTREAL, Sept. 19, 2022 – Theratechnologies (THTX) announced that their CEO, Paul Levesque, will join the "Novel Targets in Oncology: Risk vs. Reward" panel at the Cantor Oncology Conference on September 28, 2022, at 9:00 a.m. ET in New York City. The event is exclusive to conference attendees. Alongside Levesque, CFO Philippe Dubuc and CMO Dr. Christian Marsolais will engage in various meetings during the conference. Theratechnologies focuses on developing innovative therapies for unmet medical needs, emphasizing their commitment to advancements in health.

Theratechnologies has published a preclinical study demonstrating that its investigational drug TH1902 exhibits superior anticancer activity against ovarian and triple-negative breast cancer stem-like cells compared to docetaxel. The study suggests TH1902 can bypass resistance mechanisms associated with traditional chemotherapy, potentially reducing tumor growth by 80% in preclinical models. Having received FDA Fast-Track Designation, TH1902 is currently in a Phase 1 trial across multiple solid tumors, marking a significant advancement in targeting cancer stem cells.

Theratechnologies (NASDAQ: THTX) will participate in the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 1:00 p.m. ET. Paul Levesque, CEO, will engage in a fireside chat during the event. Interested investors can access the live webcast here, with an archive available for 90 days following the conference.

Theratechnologies (THTX) presented new data at the AIDS 2022 conference showing that Trogarzo (ibalizumab) maintains long-term viral suppression in HIV patients, regardless of partially active agents. Predictive pharmacokinetic modeling indicated that new administration methods could mimic intravenous infusion kinetics. The data also demonstrated synergistic effects between Trogarzo and various antiretrovirals, such as dolutegravir and lenacapavir. These findings suggest potential improvements in treatment regimens for heavily treatment-experienced HIV populations, aiming for simpler and more effective therapies.

Theratechnologies has secured $40 million through its credit agreement with Marathon Asset Management. This funding will assist in purchasing $30 million of convertible notes due in June 2023. The company also has a commitment for a non-dilutive term loan of up to $100 million, available in four tranches. The first tranche has been drawn, which is vital for its operational financing and growth. Investors are urged to consider the risks mentioned in the company’s filings on SEDAR and EDGAR.

Theratechnologies reported a Q2 2022 revenue growth of 8.3% to $19.3 million, while year-to-date revenue climbed by 13.9% to $37.8 million. The company achieved a significant 21.5% increase in EGRIFTA SV® sales. Key developments include the initiation of the TH1902 Basket Trial and a $100 million non-dilutive term loan to strengthen its financial position. The revised FY2022 revenue guidance is set between $79 million and $82 million, reflecting a positive outlook despite operational challenges.

MONTREAL, July 14, 2022 – Theratechnologies (THTX) announced updates on its TH1902 Phase 1 clinical safety study, confirming a favorable safety profile at 300 mg/m², consistent with previous animal studies. Early efficacy signs were noted in heavily pretreated patients, with confirmed partial responses in prostate cancer cases. Six major cancer centers are now active trial sites. Notably, TH1902's targeted delivery mechanism shows the potential for significantly increased drug accumulation in cancer cells, promising advancements in treating sortilin-expressing tumors.

Theratechnologies (TSX: TH, NASDAQ: THTX) announced a binding commitment for a non-dilutive term loan of up to $100 million from Marathon Asset Management. The initial draw of $40 million will help retire $30 million of convertible notes due in 2023. This financing aims to strengthen the company's balance sheet and extend its cash runway, supporting the advancement of its oncology pipeline and growth of existing products, EGRIFTA SV and Trogarzo. The loan agreement has a five-year term with several tranches available based on performance milestones.

Theratechnologies has announced a collaborative research project, funded with nearly CAN $2 million, to explore the efficacy and safety of TH1902 for metastatic cancer treatment. The initiative, supported by several organizations including the Quebec Breast Cancer Foundation and MEI, aims to enhance the therapeutic arsenal for patients with hard-to-treat cancers like triple-negative breast cancer. Led by Professor Borhane Annabi at UQAM, this project capitalizes on prior research success and seeks to improve the quality of life for cancer patients.